Workflow
Biomedical Industry Chain
icon
Search documents
预计未来5年,烟台将有13款以上1类新药获批上市
Qi Lu Wan Bao Wang· 2025-09-10 11:39
Core Insights - Yantai has integrated the biopharmaceutical industry into its "9+N" manufacturing cluster initiative, enhancing innovation and competitiveness through a structured approach involving leadership, departmental responsibilities, and coordinated support [1][3] Industry Overview - The biopharmaceutical sector in Yantai has reached 212 regulated enterprises, including 6 listed companies, 1 unicorn, 23 gazelle companies, and 9 national-level specialized and innovative small giant enterprises [3] - Yantai's biopharmaceutical industry has been recognized as a national strategic emerging industry cluster and has been included in the first batch of pillar industry clusters in Shandong Province [3] Infrastructure Development - Yantai is developing a "Blue Pharmaceutical Valley" with a planned investment of 12 billion yuan and a construction area of 1.3 million square meters, which has already attracted 34 biopharmaceutical companies [4] - Several specialized parks are under construction, including the IVD medical device industrial park and the international biopharmaceutical valley, contributing to the growth of major enterprises [4] Innovation Ecosystem - Yantai has established a vertical ecosystem for the biopharmaceutical industry, covering the entire chain from product research and development to sales [5] - The city has launched 6 first-class new drugs in recent years and anticipates over 13 more to be approved in the next five years, promoting the "Innovative Good Medicine, Yantai Manufacturing" brand [5] Strategic Focus Areas - Yantai is focusing on two major innovation tracks: medical isotopes and radioactive drugs, as well as cell and gene therapy, while also nurturing high-end generics and medical devices [6] - The Blue Pharmaceutical Valley is the largest domestic park with nuclear drug production qualifications, housing 12 first-class nuclear drugs in clinical trials [6]